Patient Guide for ICER Review of New Migraine Medicine

Background: The Institute for Clinical and Economic Review (ICER) is assessing a new migraine treatment option to determine if it is cost-effective. The medicine, erenumab, is the first CGRP submitted for FDA approval, and a regulatory decision is expected in May 2018.

Purpose: Insurance companies will use ICER’s final report (as well as other information) when determining if they will cover this medicine (and other medicines in this class that are expected to follow), what tier the medicine will be in on the plan’s formulary, and what types of prior authorization or step therapy will be required. All of this will heavily impact the access migraine patients have to this new class of medicines.  

ICER will be receiving lots of information from biotech companies, health economists, health plans, doctors, nurses and others as part of this effort. It is critically important that ICER also gets a good understanding of the migraine patient experience. You can help.

Call to Action: Patient input must be received by November 30, 2017. Yes, this is an incredibly short amount of time to take part in this process as a patient. You can access the submission form here.

This is your story to tell and a chance to be heard and advocate. Everyone’s story will be different, but it’s important that we all emphasize key points to show that we are a strong and united community. We need ICER to understand what it is like to live with migraine disease and how much need there is for better treatment options. Below are our suggestions of key points to cover in your submission to ICER.

Have Questions? A teleconference to educate patients and to answer your questions about the ICER Open Input period will be held on Tuesday, November 28 at 3:00pm ET. Click here to register for this free conference call.

Another resource for your questions is migraine patient advocate Katie Golden, who led the development of this Patient Guide. You can contact Katie through her blog, Golden Graine.

Source: https://www.headachemigraineforum.org/advo...